CytomX Therapeutics, Inc. 4

Chief Legal Officer Alejandra Carvajal received 100,000 RSUs and 450,000 stock options in CytomX Therapeutics, Inc. as equity compensation on August 3, 2026.

On August 3, 2026, CytomX Therapeutics, Inc. Chief Legal Officer Alejandra Carvajal received an equity compensation package consisting of 100,000 restricted stock units (RSUs) and a stock option grant for 450,000 shares of common stock at an exercise price of $3.17 per share, both reported as acquisitions on Form 4. The RSUs entitle her to one share of common stock per unit upon vesting, with 25% vesting annually each September 15 starting in 2027, contingent on continued service. The stock options vest 25% on the one-year anniversary of the August 3, 2026 vesting commencement date and then in equal monthly installments over the following three years until fully vested by the fourth anniversary, also subject to continued service. Following these grants, she holds 450,000 stock options and 100,000 RSUs, reflecting a sizable, service-based incentive alignment rather than an open-market purchase or sale.

Filing Facts

CIK

1501989

Ticker

CTMX

Form

4

Source Type

fda

Accession

0001610717-26-000351

Alert Tier

6